Organon & CO Schedule 13G passive stakes

Vanguard Portfolio Management has reported a beneficial ownership of 5.77% in Organon & Co's common stock as of June 30, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.26% of Organon & Co's common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 22,052,559 shares, representing 8.47% of Organon & Co's common stock, as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Organon & Co following an internal realignment that disaggregated reporting responsibilities.

The Vanguard Group has disclosed a 13.82% beneficial ownership stake in Organon & Co, holding over 35.9 million shares as of September 30, 2025.

BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, revealing a beneficial ownership of 11.9% in Organon & Co.'s common stock as of March 31, 2025.